FoxO3a在非小细胞肺癌治疗中的研究进展  

Research progress on FoxO3a in the treatment of non-small cell lung cancer

作　　者：施锦涛 沈纹君 张静霞[1] Shi Jintao;Shen Wenjun;Zhang Jingxia(School of basic medicine,Putian college,Putian,Fujian,351100,China)

机构地区：[1]莆田学院基础医学院,福建莆田351100

出　　处：《齐齐哈尔医学院学报》2021年第17期1518-1521,共4页Journal of Qiqihar Medical University

基　　金：福建省教育厅中青年教师教育科研项目(JAT170515)。

摘　　要：非小细胞肺癌(NSCLC)约占肺癌总发病率的85%,高发病率和高死亡率使其成为全球癌症相关死亡最主要的原因。FoxO3a是人类FoxO家族活性最强的成员,参与到多种生理病理过程当中。研究表明,FoxO3a在NSCLC中发挥着至关重要的作用,其主要在细胞凋亡、细胞自噬、细胞周期三个方面参与抗癌药物的作用,同时也参与NSCLC对于抗癌药物耐药性的调节。考虑到FoxO3a相关的分子调节网络十分复杂,当前尚需进一步研究FoxO3a在NSCLC发生发展过程中的影响,以便开发出一种有效的基于FoxO3a的治疗策略。将来,FoxO3a的临床应用也许能为NSCLC提供一种有效的治疗手段。Non-small cell lung cancer(NSCLC)accounts for about 85%of the total lung cancer incidence rate.High incidence rate and high mortality rate make it the leading cause of cancer related death worldwide.FoxO3a is the most active member of human FOXO family,which participates in a variety of physiological and pathological processes.Studies have shown that FoxO3a plays an important role in NSCLC.FoxO3a mainly participates in the role of anticancer drugs in three aspects of apoptosis,autophagy and cell cycle,and also participates in the regulation of NSCLC for anticancer drug resistance.Considering the complexity of FoxO3a related molecular regulatory network,it is necessary to further study the effect of FoxO3a on the occurrence and development of NSCLC,so as to develop an effective therapeutic strategy based on FoxO3a.In the future,the clinical application of FoxO3a may provide an effective treatment for NSCLC.

关 键 词：非小细胞肺癌 肺癌 FOXO FOXO3A 

分 类 号：R734.2[医药卫生—肿瘤]